SL Science Holding Limited Ordinary Shares (SLBT)
Stock · NASDAQ · Health Care
$2.7as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$2.65
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fundamentals
- Market cap
- $1.84B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
SL Science Holding Limited Ordinary Shares Competitors
Chosen by industry and closest market cap.
- SLBTSL Science Holding Limited Ordinary Shares$2.7▲ 2.27%Market cap $1.84BP/E —
- MESOMesoblast Limited American Depositary Shares$17.42▼ 4.18%Market cap $1.87BP/E —$1.88$3.31
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.33▼ 3.20%Market cap $1.69BP/E —$2.77$7.18
- COAGHemab Therapeutics Holdings Inc. Common Stock$44.77▼ 9.55%Market cap $2.10BP/E —$23$55.42
- GLUEMonte Rosa Therapeutics Inc. Common Stock$13.37▼ 6.63%Market cap $1.30BP/E —$4.6$25.77
- INBXInhibrx Biosciences Inc. Common Stock$123.93▼ 0.00%Market cap $1.21BP/E —$26.19$155.29
- IMTXImmatics N.V. Ordinary Shares$9.45▲ 0.91%Market cap $1.21BP/E —$5.05$12.41
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SLBT SL Science Holding Limited Ordinary Shares | $1.84B | — | $2.7 | ▲ 2.27% | |
| MESO Mesoblast Limited American Depositary Shares | $1.87B | — | $17.42 | ▼ 4.18% | $1.88$3.31 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.33 | ▼ 3.20% | $2.77$7.18 |
| COAG Hemab Therapeutics Holdings Inc. Common Stock | $2.10B | — | $44.77 | ▼ 9.55% | $23$55.42 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.30B | — | $13.37 | ▼ 6.63% | $4.6$25.77 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.21B | — | $123.93 | ▼ 0.00% | $26.19$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.21B | — | $9.45 | ▲ 0.91% | $5.05$12.41 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in GlioblastomaYahoo · 8/11/2026
- SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In GlioblastomaBenzinga · 8/11/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 8/3/2026
See the full, filterable feed with live charts on the MarketWall dashboard.